Cite
Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer.
MLA
Weiten, Richard, et al. “Preclinical Evidence for the Use of Anti‐Trop‐2 Antibody‐drug Conjugate Sacituzumab Govitecan in Cerebral Metastasized Castration‐resistant Prostate Cancer.” Cancer Medicine, vol. 13, no. 12, June 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1002/cam4.7320.
APA
Weiten, R., Niemann, M., Below, E., Friker, L. L., Ralser, D. J., Toma, M., Kristiansen, G., Hahn, O., Zechel, S., Grünwald, V., Bald, T., Siewert, J., Pietsch, T., Ritter, M., Hölzel, M., Eckstein, M., Alajati, A., Krausewitz, P., & Klümper, N. (2024). Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer. Cancer Medicine, 13(12), 1–9. https://doi.org/10.1002/cam4.7320
Chicago
Weiten, Richard, Max Niemann, Eduard Below, Lea L. Friker, Damian J. Ralser, Marieta Toma, Glen Kristiansen, et al. 2024. “Preclinical Evidence for the Use of Anti‐Trop‐2 Antibody‐drug Conjugate Sacituzumab Govitecan in Cerebral Metastasized Castration‐resistant Prostate Cancer.” Cancer Medicine 13 (12): 1–9. doi:10.1002/cam4.7320.